Visit The Wagner Lab

The Wagner lab studies how blood cells respond to injury or stressful situations and initiate defensive or reparatory processes. Specifically, they investigate the crucial role of cellular adhesion interactions in the response process, as well as the regulation of the adhesion molecules involved in normal physiology and in pathological situations.

Blood cells called platelets form a platelet plug to stop bleeding. Leukocytes (white blood cells) emigrate from the blood vessels to fight invading infectious agents and/or release biological mediators that stimulate the function of the surrounding organ to better respond to the demands of stress. All this requires activation of adhesive processes that allow vascular cells to bind to each other and to cells in the organs where the leukocytes emigrate.

To advance their work, Wagner and colleagues have engineered mice lacking platelet, endothelial, or leukocyte adhesion receptors. These animals permit modeling of human diseases with similar genetic defects and evaluation of the performance of mutant blood cells in live vessels through intravital microscopy. The Wagner lab studies platelet adhesion to the vessel wall, which can lead to thrombus formation and sometimes embolization. Recently, they observed that nuclear DNA ejected by stimulated leukocytes (NETs) greatly enhanced pathological thrombosis and organ injury during inflammation.

Wagner and colleagues also are researching the importance of adhesion molecules in inflammatory processes such as atherosclerosis, the narrowing of arteries. They have observed that leukocytes recruited to the liver help to regulate fat metabolism and help to prevent obesity. The lab began to visualize blood vessels in the brain and study mechanisms involved in the formation of the blood brain barrier, which prevents uncontrolled leakage of molecules from the blood into the central nervous system. They ask, do malfunctions of brain microcirculation contribute to the etiology of neurodegenerative diseases such as Alzheimer's? Using animal models, they are testing new ways to modulate blood brain barrier permeability and to evaluate inhibitors of adhesion molecules as possible agents to prevent heart disease and/or thrombosis.


Dr. Wagner received her Diploma of Biochemistry from the Université de Geneve, Switzerland and Ph.D. in Biology from the Massachusetts Institute of Technology. She served on the faculty at the University of Rochester, NY and Tufts University School of Medicine before coming to Harvard Medical School in 1994.  She is the Edwin Cohn Professor of Pediatrics, a senior investigator in the Program in Cellular and Molecular Medicine, and a member of the Division of Hematology/Oncology at Boston Children's Hospital.


Publications powered by Harvard Catalyst Profiles

  1. The role of platelets in thrombus fibrosis and vessel wall remodeling after venous thrombosis. J Thromb Haemost. 2021 02; 19(2):387-399. View abstract
  2. Reply to Liu: The disassembly of the actin cytoskeleton is an early event during NETosis. Proc Natl Acad Sci U S A. 2020 09 15; 117(37):22655-22656. View abstract
  3. Cellular Mechanisms of NETosis. Annu Rev Cell Dev Biol. 2020 10 06; 36:191-218. View abstract
  4. NETosis proceeds by cytoskeleton and endomembrane disassembly and PAD4-mediated chromatin decondensation and nuclear envelope rupture. Proc Natl Acad Sci U S A. 2020 03 31; 117(13):7326-7337. View abstract
  5. Recombinant human ADAMTS13 treatment and anti-NET strategies enhance skin allograft survival in mice. Am J Transplant. 2020 04; 20(4):1162-1169. View abstract
  6. Resolvin D4 attenuates the severity of pathological thrombosis in mice. Blood. 2019 10 24; 134(17):1458-1468. View abstract
  7. Extracellular DNA NET-Works With Dire Consequences for Health. Circ Res. 2019 08 02; 125(4):470-488. View abstract
  8. Plasma Peptidylarginine Deiminase IV Promotes VWF-Platelet String Formation and Accelerates Thrombosis After Vessel Injury. Circ Res. 2019 08 16; 125(5):507-519. View abstract
  9. Solid peripheral tumor leads to systemic inflammation, astrocyte activation and signs of behavioral despair in mice. PLoS One. 2018; 13(11):e0207241. View abstract
  10. Neutrophil cytoplasts induce TH17 differentiation and skew inflammation toward neutrophilia in severe asthma. Sci Immunol. 2018 08 03; 3(26). View abstract
  11. Peptidylarginine deiminase 4: a nuclear button triggering neutrophil extracellular traps in inflammatory diseases and aging. FASEB J. 2018 Jun 20; fj201800691R. View abstract
  12. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018 04 11; 10(436). View abstract
  13. Roles of PAD4 and NETosis in Experimental Atherosclerosis and Arterial Injury: Implications for Superficial Erosion. Circ Res. 2018 06 22; 123(1):33-42. View abstract
  14. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. J Thromb Haemost. 2018 03; 16(3):508-518. View abstract
  15. Recombinant Human ADAMTS13 Treatment Improves Myocardial Remodeling and Functionality After Pressure Overload Injury in Mice. J Am Heart Assoc. 2018 01 24; 7(3). View abstract
  16. Sirt3 deficiency does not affect venous thrombosis or NETosis despite mild elevation of intracellular ROS in platelets and neutrophils in mice. PLoS One. 2017; 12(12):e0188341. View abstract
  17. A key role for Rac and Pak signaling in neutrophil extracellular traps (NETs) formation defines a new potential therapeutic target. Am J Hematol. 2018 02; 93(2):269-276. View abstract
  18. Unraveling Vascular Inflammation: From Immunology to Imaging. J Am Coll Cardiol. 2017 Sep 12; 70(11):1403-1412. View abstract
  19. Mast Cells Granular Contents Are Crucial for Deep Vein Thrombosis in Mice. Circ Res. 2017 Sep 29; 121(8):941-950. View abstract
  20. ADAMTS13 Deficiency Worsens Colitis and Exogenous ADAMTS13 Administration Decreases Colitis Severity in Mice. TH Open. 2017 Jun; 1(1):e11-e23. View abstract
  21. Peptidylarginine deiminase 4 promotes age-related organ fibrosis. J Exp Med. 2017 02; 214(2):439-458. View abstract
  22. PAD4 Deficiency Decreases Inflammation and Susceptibility to Pregnancy Loss in a Mouse Model. Biol Reprod. 2016 12; 95(6):132. View abstract
  23. Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice. Blood. 2016 08 04; 128(5):721-31. View abstract
  24. Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease. Science. 2016 Apr 22; 352(6284):463-6. View abstract
  25. Priming of neutrophils toward NETosis promotes tumor growth. Oncoimmunology. 2016 May; 5(5):e1134073. View abstract
  26. NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation. Thromb Res. 2016 Mar; 139:56-64. View abstract
  27. Flow cytometric assay for direct quantification of neutrophil extracellular traps in blood samples. Am J Hematol. 2015 Dec; 90(12):1155-8. View abstract
  28. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nat Med. 2015 Jul; 21(7):815-9. View abstract
  29. ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy. J Am Soc Nephrol. 2016 Jan; 27(1):120-31. View abstract
  30. P-selectin promotes neutrophil extracellular trap formation in mice. Blood. 2015 Jul 09; 126(2):242-6. View abstract
  31. PAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shock. Blood. 2015 Mar 19; 125(12):1948-56. View abstract
  32. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015 Mar; 11(3):189-91. View abstract
  33. Dietary omega-3 alpha-linolenic acid does not prevent venous thrombosis in mice. Thromb Haemost. 2015 Jan; 113(1):177-84. View abstract
  34. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood. 2014 Jun 12; 123(24):3818-27. View abstract
  35. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost. 2014 Apr; 40(3):277-83. View abstract
  36. Thrombosis: tangled up in NETs. Blood. 2014 May 01; 123(18):2768-76. View abstract
  37. VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. Blood. 2014 Jan 02; 123(1):141-8. View abstract
  38. Endothelial Von Willebrand factor promotes blood-brain barrier flexibility and provides protection from hypoxia and seizures in mice. Arterioscler Thromb Vasc Biol. 2013 Sep; 33(9):2112-20. View abstract
  39. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol. 2013 Aug; 33(8):2032-2040. View abstract
  40. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A. 2013 May 21; 110(21):8674-9. View abstract
  41. Neutrophils release extracellular DNA traps during storage of red blood cell units. Transfusion. 2013 Dec; 53(12):3210-6. View abstract
  42. Lack of tryptophan hydroxylase-1 in mice results in gait abnormalities. PLoS One. 2013; 8(3):e59032. View abstract
  43. Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology. 2013 Feb 01; 2(2):e22946. View abstract
  44. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood. 2013 Feb 07; 121(6):1008-15. View abstract
  45. Isoflurane inhibits neutrophil recruitment in the cutaneous Arthus reaction model. J Anesth. 2013 Apr; 27(2):261-8. View abstract
  46. Endocytosis of soluble immune complexes leads to their clearance by Fc?RIIIB but induces neutrophil extracellular traps via Fc?RIIA in vivo. Blood. 2012 Nov 22; 120(22):4421-31. View abstract
  47. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood. 2012 Dec 20; 120(26):5217-23. View abstract
  48. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012 Aug 07; 109(32):13076-81. View abstract
  49. ADAMTS13 exerts a thrombolytic effect in microcirculation. Thromb Haemost. 2012 Sep; 108(3):527-32. View abstract
  50. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science. 2012 Aug 10; 337(6095):738-42. View abstract
  51. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2012 Aug; 32(8):1777-83. View abstract
  52. Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice. Arterioscler Thromb Vasc Biol. 2012 Aug; 32(8):1841-7. View abstract
  53. Extracellular chromatin is an important mediator of ischemic stroke in mice. Arterioscler Thromb Vasc Biol. 2012 Aug; 32(8):1884-91. View abstract
  54. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood. 2012 Aug 09; 120(6):1157-64. View abstract
  55. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood. 2012 Jun 28; 119(26):6335-43. View abstract
  56. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012 Apr 09; 209(4):819-35. View abstract
  57. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol. 2012 Apr; 32(4):902-9. View abstract
  58. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012 Jan; 10(1):136-44. View abstract
  59. Targeting platelet function to improve drug delivery. Oncoimmunology. 2012 Jan 01; 1(1):100-102. View abstract
  60. von Willebrand factor: an emerging target in stroke therapy. Stroke. 2012 Feb; 43(2):599-606. View abstract
  61. Desialylation accelerates platelet clearance after refrigeration and initiates GPIba metalloproteinase-mediated cleavage in mice. Blood. 2012 Feb 02; 119(5):1263-73. View abstract
  62. Platelet glycoprotein Iba is an important mediator of ischemic stroke in mice. Exp Transl Stroke Med. 2011 Sep 13; 3:9. View abstract
  63. How platelets safeguard vascular integrity. J Thromb Haemost. 2011 Jul; 9 Suppl 1:56-65. View abstract
  64. Histones induce rapid and profound thrombocytopenia in mice. Blood. 2011 Sep 29; 118(13):3708-14. View abstract
  65. Rap1a activation by CalDAG-GEFI and p38 MAPK is involved in E-selectin-dependent slow leukocyte rolling. Eur J Immunol. 2011 Jul; 41(7):2074-85. View abstract
  66. The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood. 2011 Jun 09; 117(23):6326-37. View abstract
  67. Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res. 2011 Mar 01; 71(5):1540-9. View abstract
  68. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011 Jan 27; 117(4):1400-7. View abstract
  69. The lack of ADAM17 activity during embryonic development causes hemorrhage and impairs vessel formation. PLoS One. 2010 Oct 15; 5(10):e13433. View abstract
  70. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010 Sep 07; 107(36):15880-5. View abstract
  71. A novel interaction between FlnA and Syk regulates platelet ITAM-mediated receptor signaling and function. J Exp Med. 2010 Aug 30; 207(9):1967-79. View abstract
  72. Integrin-independent role of CalDAG-GEFI in neutrophil chemotaxis. J Leukoc Biol. 2010 Aug; 88(2):313-9. View abstract
  73. p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo. Blood. 2010 Mar 04; 115(9):1835-42. View abstract
  74. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am J Pathol. 2009 Oct; 175(4):1699-708. View abstract
  75. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood. 2009 Oct 08; 114(15):3329-34. View abstract
  76. Platelets: guardians of tumor vasculature. Cancer Res. 2009 Jul 15; 69(14):5623-6. View abstract
  77. Differential stimulation of monocytic cells results in distinct populations of microparticles. J Thromb Haemost. 2009 Jun; 7(6):1019-28. View abstract
  78. Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion. Cardiovasc Res. 2009 Oct 01; 84(1):137-44. View abstract
  79. Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol. 2009 Aug; 29(8):1185-92. View abstract
  80. Serotonin stimulates platelet receptor shedding by tumor necrosis factor-alpha-converting enzyme (ADAM17). J Thromb Haemost. 2009 Jul; 7(7):1163-71. View abstract
  81. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost. 2009 Jul; 7(7):1155-62. View abstract
  82. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood. 2009 Jun 04; 113(23):6015-22. View abstract
  83. The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood. 2009 May 21; 113(21):5323-9. View abstract
  84. The effect of C1 inhibitor on intestinal ischemia and reperfusion injury. Am J Physiol Gastrointest Liver Physiol. 2008 Nov; 295(5):G1042-9. View abstract
  85. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res. 2008 Aug 15; 68(16):6851-8. View abstract
  86. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med. 2008 Sep 01; 205(9):2065-74. View abstract
  87. Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis. Circ Res. 2008 Sep 12; 103(6):598-605. View abstract
  88. von-Willebrand factor influences blood brain barrier permeability and brain inflammation in experimental allergic encephalomyelitis. Am J Pathol. 2008 Sep; 173(3):892-900. View abstract
  89. CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets. Blood. 2008 Sep 01; 112(5):1696-703. View abstract
  90. The vessel wall and its interactions. Blood. 2008 Jun 01; 111(11):5271-81. View abstract
  91. Thrombocytopenia and platelet abnormalities in high-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008 Jun; 28(6):1111-6. View abstract
  92. Inflammation induces hemorrhage in thrombocytopenia. Blood. 2008 May 15; 111(10):4958-64. View abstract
  93. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost. 2008 Feb; 99(2):264-70. View abstract
  94. [Evaluation of T-cell interferon-gamma-release assays for the diagnosis of latent and active tuberculosis]. Dtsch Med Wochenschr. 2008 Feb; 133(8):354-7. View abstract
  95. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood. 2008 Apr 01; 111(7):3452-7. View abstract
  96. Prothrombotic effects of fibronectin isoforms containing the EDA domain. Arterioscler Thromb Vasc Biol. 2008 Feb; 28(2):296-301. View abstract
  97. Platelet adhesion receptors do not modulate infarct volume after a photochemically induced stroke in mice. Brain Res. 2007 Dec 14; 1185:239-45. View abstract
  98. PSGL-1 regulates platelet P-selectin-mediated endothelial activation and shedding of P-selectin from activated platelets. Thromb Haemost. 2007 Oct; 98(4):806-12. View abstract
  99. Dynamic visualization of thrombopoiesis within bone marrow. Science. 2007 Sep 21; 317(5845):1767-70. View abstract
  100. Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J Clin Invest. 2007 Jun; 117(6):1699-707. View abstract
  101. [Coil embolization of arteriovenous fistulae on in situ saphenous vein bypasses: success rate and complications]. Rofo. 2007 Jun; 179(6):587-92. View abstract
  102. In vitro function and phagocytosis of galactosylated platelet concentrates after long-term refrigeration. Transfusion. 2007 Mar; 47(3):442-51. View abstract
  103. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol. 2007 Apr; 27(4):728-39. View abstract
  104. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci U S A. 2007 Jan 30; 104(5):1621-6. View abstract
  105. Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost. 2007 Mar; 5(3):583-9. View abstract
  106. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood. 2007 Mar 15; 109(6):2424-9. View abstract
  107. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A. 2006 Nov 07; 103(45):16900-5. View abstract
  108. Mac-1 signaling via Src-family and Syk kinases results in elastase-dependent thrombohemorrhagic vasculopathy. Immunity. 2006 Aug; 25(2):271-83. View abstract
  109. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. . 2007 Apr; 292(4):C1256-62. View abstract
  110. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost. 2006 Oct; 4(10):2230-7. View abstract
  111. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest. 2006 Jul; 116(7):1913-23. View abstract
  112. Serum mannose-binding lectin deficiency is associated with cryptosporidiosis in young Haitian children. Clin Infect Dis. 2006 Aug 01; 43(3):289-94. View abstract
  113. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006 Mar 20; 203(3):767-76. View abstract
  114. Decreased plasma fibronectin leads to delayed thrombus growth in injured arterioles. Arterioscler Thromb Vasc Biol. 2006 Jun; 26(6):1391-6. View abstract
  115. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A. 2006 Jan 24; 103(4):855-60. View abstract
  116. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005 Oct; 115(10):2752-61. View abstract
  117. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood. 2006 Jan 15; 107(2):591-3. View abstract
  118. Aspirin induces platelet receptor shedding via ADAM17 (TACE). J Biol Chem. 2005 Dec 02; 280(48):39716-22. View abstract
  119. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost. 2005 Aug; 3(8):1590-6. View abstract
  120. Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood. 2005 Oct 01; 106(7):2334-9. View abstract
  121. A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol. 2005 May 15; 174(10):6462-6. View abstract
  122. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2005 Jul; 25(7):1321-4. View abstract
  123. Elevated soluble ICAM-1 levels induce immune deficiency and increase adiposity in mice. FASEB J. 2005 Jun; 19(8):1018-20. View abstract
  124. Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. Ren Fail. 2005; 27(4):385-92. View abstract
  125. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res. 2004 Oct 01; 95(7):677-83. View abstract
  126. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med. 2004 Sep; 10(9):982-6. View abstract
  127. ICAM-1 and beta2 integrin deficiency impairs fat oxidation and insulin metabolism during fasting. Mol Med. 2004 Jul-Dec; 10(7-12):72-9. View abstract
  128. GPVI down-regulation in murine platelets through metalloproteinase-dependent shedding. Thromb Haemost. 2004 May; 91(5):951-8. View abstract
  129. Mice lacking insulin or insulin-like growth factor 1 receptors in vascular endothelial cells maintain normal blood-brain barrier. Biochem Biophys Res Commun. 2004 Apr 30; 317(2):315-20. View abstract
  130. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med. 2004 Apr; 10(4):179-86. View abstract
  131. Antithrombotic activity of TNF-alpha. J Clin Invest. 2003 Nov; 112(10):1589-96. View abstract
  132. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003 Nov; 38(5):1075-89. View abstract
  133. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell. 2003 Oct 17; 115(2):139-50. View abstract
  134. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003 Dec; 23(12):2131-7. View abstract
  135. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood. 2003 Dec 01; 102(12):4229-35. View abstract
  136. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med. 2003 Aug; 9(8):1020-5. View abstract
  137. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood. 2003 Nov 15; 102(10):3609-14. View abstract
  138. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A. 2003 Mar 04; 100(5):2415-9. View abstract
  139. Mechanisms and implications of platelet discoid shape. Blood. 2003 Jun 15; 101(12):4789-96. View abstract
  140. The clearance mechanism of chilled blood platelets. Cell. 2003 Jan 10; 112(1):87-97. View abstract
  141. Platelet P-selectin facilitates atherosclerotic lesion development. Blood. 2003 Apr 01; 101(7):2661-6. View abstract
  142. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood. 2002 Aug 15; 100(4):1340-6. View abstract
  143. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci. 2002 Apr; 43(4):1135-41. View abstract
  144. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med. 2002 Mar; 8(3):247-52. View abstract
  145. ApoE deficiency compromises the blood brain barrier especially after injury. Mol Med. 2001 Dec; 7(12):810-5. View abstract
  146. The isolation of antibiotic-resistant salmonella from retail ground meats. N Engl J Med. 2001 Oct 18; 345(16):1147-54. View abstract
  147. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood. 2001 Sep 01; 98(5):1424-8. View abstract
  148. Increased thrombogenesis and embolus formation in mice lacking glycoprotein V. Blood. 2001 Jul 15; 98(2):368-73. View abstract
  149. Infection-mediated early-onset periodontal disease in P/E-selectin-deficient mice. J Clin Periodontol. 2001 Jun; 28(6):569-75. View abstract
  150. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc Natl Acad Sci U S A. 2001 Mar 27; 98(7):4072-7. View abstract
  151. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Blood. 2001 Jan 15; 97(2):465-72. View abstract
  152. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000 Dec 05; 97(25):13835-40. View abstract
  153. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 2000 Nov 15; 96(10):3322-8. View abstract
  154. Sleep and wakefulness in c-fos and fos B gene knockout mice. Brain Res Mol Brain Res. 2000 Aug 14; 80(1):75-87. View abstract
  155. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000 Aug; 106(3):385-92. View abstract
  156. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation. 2000 May 16; 101(19):2290-5. View abstract
  157. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med. 2000 Apr 17; 191(8):1413-22. View abstract
  158. Distribution of hypocretin-containing neurons in the lateral hypothalamus and C-fos-immunoreactive neurons in the VLPO. Sleep Res Online. 2000; 3(1):35-42. View abstract
  159. Carboxypeptidase E does not mediate von Willebrand factor targeting to storage granules. Eur J Cell Biol. 1999 Dec; 78(12):884-91. View abstract
  160. Insights from von Willebrand disease animal models. Cell Mol Life Sci. 1999 Dec; 56(11-12):977-90. View abstract
  161. Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leukocyte recruitment. Proc Natl Acad Sci U S A. 1999 Sep 28; 96(20):11452-7. View abstract
  162. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med. 1999 Sep; 5(9):1010-7. View abstract
  163. New discoveries with mice mutant in endothelial and platelet selectins. Thromb Haemost. 1999 Aug; 82(2):850-7. View abstract
  164. P- and E-selectin-deficient mice are susceptible to cerebral ischemia-reperfusion injury. Brain Res. 1999 Jul 24; 835(2):360-4. View abstract
  165. Donor MHC and adhesion molecules in transplant arteriosclerosis. J Clin Invest. 1999 Feb; 103(4):469-74. View abstract
  166. Selective eosinophil transendothelial migration triggered by eotaxin via modulation of Mac-1/ICAM-1 and VLA-4/VCAM-1 interactions. Int Immunol. 1999 Jan; 11(1):1-10. View abstract
  167. P-Selectin and platelet clearance. Blood. 1998 Dec 01; 92(11):4446-52. View abstract
  168. Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. Proc Natl Acad Sci U S A. 1998 Nov 24; 95(24):14423-8. View abstract
  169. Role of P-selectin cytoplasmic domain in granular targeting in vivo and in early inflammatory responses. J Cell Biol. 1998 Nov 16; 143(4):1129-41. View abstract
  170. Leukocyte-endothelium adhesion molecules in atherosclerosis. J Lab Clin Med. 1998 Nov; 132(5):369-75. View abstract
  171. Overlapping functions of E- and P-selectin in neutrophil recruitment during acute inflammation. Blood. 1998 Oct 01; 92(7):2345-52. View abstract
  172. E and P selectins are not required for resistance to severe murine lyme arthritis. Infect Immun. 1998 Sep; 66(9):4557-9. View abstract
  173. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998 Aug 04; 95(16):9524-9. View abstract
  174. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med. 1998 Aug 03; 188(3):465-74. View abstract
  175. Determination of endogenous growth factors in human wound fluid: temporal presence and profiles of secretion. Plast Reconstr Surg. 1998 Jul; 102(1):117-23. View abstract
  176. The combined role of P- and E-selectins in atherosclerosis. J Clin Invest. 1998 Jul 01; 102(1):145-52. View abstract
  177. The transmembrane domain enhances granular targeting of P-selectin. Eur J Cell Biol. 1998 Apr; 75(4):331-43. View abstract
  178. Growth factors and insulin-like growth factor binding proteins in acute wound fluid. Growth Horm IGF Res. 1998 Apr; 8 Suppl B:107-9. View abstract
  179. P- and E-selectins are required for the leukocyte recruitment, but not the tissue swelling, associated with IgE- and mast cell-dependent inflammation in mouse skin. Lab Invest. 1998 Apr; 78(4):497-505. View abstract
  180. Platelet-endothelial interactions in inflamed mesenteric venules. Blood. 1998 Feb 15; 91(4):1318-24. View abstract
  181. Angiogenesis in P- and E-selectin-deficient mice. Microcirculation. 1998; 5(2-3):173-8. View abstract
  182. Leukocytes fighting against obesity. Mol Psychiatry. 1998 Jan; 3(1):8-9. View abstract
  183. Genetic manipulation of vascular adhesion molecules in mice. J Clin Invest. 1997 Dec 01; 100(11 Suppl):S11-3. View abstract
  184. Experimental murine acid aspiration injury is mediated by neutrophils and the alternative complement pathway. J Appl Physiol (1985). 1997 Oct; 83(4):1090-5. View abstract
  185. Generation and characterization of a novel adhesion function blocking monoclonal antibody recognizing both rat and mouse E-selectin. Hybridoma. 1997 Aug; 16(4):355-61. View abstract
  186. A new class of obesity genes encodes leukocyte adhesion receptors. Proc Natl Acad Sci U S A. 1997 Jul 08; 94(14):7526-30. View abstract
  187. Insights into selectin function from knockout mice. Thromb Haemost. 1997 Jul; 78(1):60-4. View abstract
  188. Characterization of a novel adhesion function blocking monoclonal antibody to rat/mouse P-selectin generated in the P-selectin-deficient mouse. Hybridoma. 1997 Jun; 16(3):249-57. View abstract
  189. Role of endothelial selectins in wound repair. Am J Pathol. 1997 May; 150(5):1701-9. View abstract
  190. L-[1-(13)C] Phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease. Am J Surg. 1997 Apr; 173(4):270-3; discussion 273-4. View abstract
  191. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest. 1997 Mar 01; 99(5):1037-43. View abstract
  192. Role of the Brn-3 family of POU-domain genes in the development of the auditory/vestibular, somatosensory, and visual systems. Cold Spring Harb Symp Quant Biol. 1997; 62:325-36. View abstract
  193. Genetic manipulation of vascular adhesion molecules in mice. J Clin Invest. 1996 Nov 15; 98(10):2193-5. View abstract
  194. Control of rod retinomotor movements in teleost retinae: the role of dopamine in mediating light-dependent and circadian signals. Cell Tissue Res. 1996 Sep; 285(3):445-51. View abstract
  195. Adhesion molecules--Part II: Blood vessels and blood cells. N Engl J Med. 1996 Jul 04; 335(1):43-5. View abstract
  196. Adhesion molecules--Part 1. N Engl J Med. 1996 Jun 06; 334(23):1526-9. View abstract
  197. Cytokine-induced meningitis is dramatically attenuated in mice deficient in endothelial selectins. J Clin Invest. 1996 Jun 01; 97(11):2485-90. View abstract
  198. Double knockout highlights value of endothelial selectins. Immunol Today. 1996 May; 17(5):205. View abstract
  199. Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int. 1996 May; 49(5):1342-9. View abstract
  200. Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell. 1996 Feb 23; 84(4):563-74. View abstract
  201. Defects in hemostasis in P-selectin-deficient mice. Blood. 1996 Feb 15; 87(4):1238-42. View abstract
  202. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest. 1996 Jan 15; 97(2):493-500. View abstract
  203. Rolling in P-selectin-deficient mice is reduced but not eliminated in the dorsal skin. Blood. 1995 Nov 01; 86(9):3487-92. View abstract
  204. Blood cell dynamics in P-selectin-deficient mice. Blood. 1995 Aug 01; 86(3):1106-14. View abstract
  205. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A. 1995 Aug 01; 92(16):7450-4. View abstract
  206. Reduced recruitment of inflammatory cells in a contact hypersensitivity response in P-selectin-deficient mice. J Exp Med. 1995 Jun 01; 181(6):2277-82. View abstract
  207. P-selectin chases a butterfly. J Clin Invest. 1995 May; 95(5):1955-6. View abstract
  208. P-selectin knockout: a mouse model for various human diseases. Ciba Found Symp. 1995; 189:2-10; discussion 10-16, 77-8. View abstract
  209. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood. 1994 Jun 15; 83(12):3536-44. View abstract
  210. Requirement for both D domains of the propolypeptide in von Willebrand factor multimerization and storage. Thromb Haemost. 1993 Dec 20; 70(6):1053-7. View abstract
  211. CD63 is a component of Weibel-Palade bodies of human endothelial cells. Blood. 1993 Aug 15; 82(4):1184-91. View abstract
  212. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell. 1993 Aug 13; 74(3):541-54. View abstract
  213. P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. J Clin Invest. 1993 Aug; 92(2):804-13. View abstract
  214. Divergent fates of P- and E-selectins after their expression on the plasma membrane. Mol Biol Cell. 1993 Aug; 4(8):791-801. View abstract
  215. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost. 1993 Jul 01; 70(1):105-10. View abstract
  216. von Willebrand factor storage requires intact prosequence cleavage site. Eur J Cell Biol. 1993 Feb; 60(1):31-41. View abstract
  217. COP1, an Arabidopsis regulatory gene, encodes a protein with both a zinc-binding motif and a G beta homologous domain. Cell. 1992 Nov 27; 71(5):791-801. View abstract
  218. P-selectin and E-selectin. Distinct but overlapping leukocyte ligand specificities. J Biol Chem. 1992 Jun 05; 267(16):11104-10. View abstract
  219. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci U S A. 1992 Apr 15; 89(8):3531-5. View abstract
  220. A 130-kDa protein on endothelial cells binds to amino acids 15-42 of the B beta chain of fibrinogen. J Biol Chem. 1992 Feb 05; 267(4):2451-8. View abstract
  221. P-selectin, a granule membrane protein of platelets and endothelial cells, follows the regulated secretory pathway in AtT-20 cells. J Cell Biol. 1992 Feb; 116(3):617-25. View abstract
  222. von Willebrand factor and the endothelium. Mayo Clin Proc. 1991 Jun; 66(6):621-7. View abstract
  223. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell. 1991 Jan 25; 64(2):403-13. View abstract
  224. von Willebrand factor biosynthesis and processing. Ann N Y Acad Sci. 1991; 614:153-66. View abstract
  225. PADGEM, a leukocyte receptor on activated platelets. Biology and application to in vivo medical diagnostics. Curr Stud Hematol Blood Transfus. 1991; (58):32-6. View abstract
  226. PADGEM-dependent adhesion of platelets to monocytes and neutrophils is mediated by a lineage-specific carbohydrate, LNF III (CD15). Cell. 1990 Nov 02; 63(3):467-74. View abstract
  227. Human endothelial cells synthesize, process, and secrete fibronectin molecules bearing an alternatively spliced type III homology (ED1). Blood. 1990 May 01; 75(9):1801-8. View abstract
  228. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990; 6:217-46. View abstract
  229. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989 Oct 20; 59(2):305-12. View abstract
  230. In vitro multimerization of von Willebrand factor is triggered by low pH. Importance of the propolypeptide and free sulfhydryls. J Biol Chem. 1989 Aug 15; 264(23):13497-503. View abstract
  231. Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin beta chain. J Clin Invest. 1989 Aug; 84(2):435-42. View abstract
  232. Temperature-sensitive steps in the secretory pathway for von Willebrand factor in endothelial cells. Eur J Cell Biol. 1989 Apr; 48(2):337-43. View abstract
  233. Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol. 1989 Apr; 108(4):1283-9. View abstract
  234. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood. 1989 Apr; 73(5):1109-12. View abstract
  235. von Willebrand factor biosynthesis and partitioning between constitutive and regulated pathways of secretion after thrombin stimulation. Blood. 1989 Feb 15; 73(3):706-11. View abstract
  236. Molecular and cellular biology of von Willebrand factor. Prog Hemost Thromb. 1989; 9:233-59. View abstract
  237. Intact microtubules are necessary for complete processing, storage and regulated secretion of von Willebrand factor by endothelial cells. Eur J Cell Biol. 1987 Jun; 43(3):377-83. View abstract
  238. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood. 1987 May; 69(5):1531-4. View abstract
  239. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A. 1987 Apr; 84(7):1955-9. View abstract
  240. Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest. 1987 Jan; 79(1):117-23. View abstract
  241. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood. 1987 Jan; 69(1):27-32. View abstract
  242. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986 Jul 18; 46(2):185-90. View abstract
  243. Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II. Science. 1986 May 23; 232(4753):995-8. View abstract
  244. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol. 1986 Apr; 102(4):1320-4. View abstract
  245. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest. 1985 Sep; 76(3):1102-6. View abstract
  246. Inhibition of disulfide bonding of von Willebrand protein by monensin results in small, functionally defective multimers. J Cell Biol. 1985 Jul; 101(1):112-20. View abstract
  247. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol. 1984 Dec; 99(6):2123-30. View abstract
  248. Irradiation induces release of von Willebrand protein from endothelial cells in culture. Blood. 1984 Aug; 64(2):567-70. View abstract
  249. Von Willebrand protein binds to extracellular matrices independently of collagen. Proc Natl Acad Sci U S A. 1984 Jan; 81(2):471-5. View abstract
  250. Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem. 1983 Feb 25; 258(4):2065-7. View abstract
  251. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol. 1982 Oct; 95(1):355-60. View abstract
  252. Fibronectin-coated beads are endocytosed by cells and align with microfilament bundles. Exp Cell Res. 1982 Aug; 140(2):373-81. View abstract
  253. Relationships between microfilaments, cell-substratum adhesion, and fibronectin. Cold Spring Harb Symp Quant Biol. 1982; 46 Pt 2:659-70. View abstract
  254. Similarities and differences between the fibronectins of normal and transformed hamster cells. J Biol Chem. 1981 Nov 25; 256(22):11708-15. View abstract
  255. Topological arrangement of the major structural features of fibronectin. J Biol Chem. 1980 May 10; 255(9):4304-12. View abstract
  256. Domain structure of fibronectin and its relation to function. Disulfides and sulfhydryl groups. J Biol Chem. 1979 Jul 25; 254(14):6746-54. View abstract
  257. Cell surface fibronectin and oncogenic transformation. J Supramol Struct. 1979; 11(1):95-104. View abstract
  258. A large glycoprotein lost from the surfaces of transformed cells. Ann N Y Acad Sci. 1978 Jun 20; 312:317-42. View abstract